MedTrace Logo

Castrate Resistant Prostate Cancer Enhertu Therapy

NCT06610825 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-13

No results posted yet for this study

Summary

Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.

Conditions

Interventions

DRUG

Enhertu

This is an open label, multi-center, single arm, phase II study designed to investigate the anti-tumor activity, efficacy and safety of Enhertu in HER2-positive metastatic castrate-resistant prostate cancer patients who progressed on androgen deprivation therapy and novel hormonal agents (such as Abiraterone and Enzalutamide), who also progressed, refused, or were not candidates to receive taxane-based chemotherapy.

Sponsors & Collaborators

  • Daiichi Sankyo

    collaborator INDUSTRY

  • Cancer Research And Biostatistics

    collaborator UNKNOWN

  • Institute for Clinical Research

    collaborator OTHER

  • Washington D.C. Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • Maneesh Jain, MD · Washington DC VA Medical Center

  • Eric Knoche, MD · VA St. Louis Healthcare System

  • Suman Kambhampati, MD · VA Kansas City

  • Julie Graff, MD · Portland VA Medical Center

  • Bruce Montgomery, MD · VA Puget Sound HCS

  • David Kosoff, MD · Wisconsin VA Medical Center

  • Kerry Schaffer, MD · Vanderbilt University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-05
Primary Completion
2027-10-31
Completion
2028-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06610825 on ClinicalTrials.gov